Literature DB >> 10510110

Comorbidity in patients with prostate cancer and its relevance to treatment choice.

P N Post1, P J Kil, A J Hendrikx, M L Janssen-Heijnen, M A Crommelin, J W Coebergh.   

Abstract

OBJECTIVE: To evaluate the prevalence of comorbidity among patients with prostate cancer in relation to tumour and patient characteristics and to assess if comorbidity was a determining factor in the treatment choice for patients with localized prostate cancer. PATIENTS AND METHODS: Serious comorbidity was recorded in the Eindhoven Cancer Registry (according to a published list of such diseases) for all patients (2941) with prostate cancer newly diagnosed between 1993 and 1996 in the southern part of The Netherlands. Logistic regression was then used to assess which factors determined the treatment choice.
RESULTS: The prevalence of at least one serious comorbid condition was 38% for patients aged 60-69 years, 48% when aged 70-74 years and 53% for those aged >/=75 years, the cardiovascular and chronic obstructive lung diseases being most frequent. Patients aged 60-69 years were more likely to be treated with radical prostatectomy for moderately differentiated tumour confined to the prostate, or when younger and diagnosed in a hospital with a high case-load. The presence of comorbidity had little influence of this choice.
CONCLUSION: Comorbidity was common in patients with prostate cancer, but the decision of urologists in the southern Netherlands to use radical prostatectomy was determined largely by the patient's age and the urologist's experience.

Entities:  

Mesh:

Year:  1999        PMID: 10510110     DOI: 10.1046/j.1464-410x.1999.00279.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  13 in total

Review 1.  [Chemotherapy in the elderly].

Authors:  G Lümmen; H Rübben
Journal:  Urologe A       Date:  2003-11       Impact factor: 0.639

2.  Watchful waiting and active surveillance approach in patients with low risk localized prostatic cancer: an experience of out-patients clinic with 12-year follow-up.

Authors:  Sergey Kravchick; Ronit Peled; Shmuel Cytron
Journal:  Pathol Oncol Res       Date:  2011-06-08       Impact factor: 3.201

3.  Impact of Comorbidities on Prostate Cancer Stage at Diagnosis in Florida.

Authors:  Hong Xiao; Fei Tan; Pierre Goovaerts; Georges Adunlin; Askal Ayalew Ali; Clement K Gwede; Youjie Huang
Journal:  Am J Mens Health       Date:  2014-12-26

4.  Prostate cancer in elderly men.

Authors:  Anton Stangelberger; Matthias Waldert; Bob Djavan
Journal:  Rev Urol       Date:  2008

5.  Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy.

Authors:  Kathryn Bylow; William Dale; Karen Mustian; Walter M Stadler; Miriam Rodin; William Hall; Mark Lachs; Supriya G Mohile
Journal:  Urology       Date:  2008-06-17       Impact factor: 2.649

6.  [Geriatric assessment. Is it significantly helpful in selection of elderly tumour patients for a difficult therapy?].

Authors:  S Krege; C Friedrich; G Lümmen; L Pientka; H Rübben
Journal:  Urologe A       Date:  2004-08       Impact factor: 0.639

7.  Personality predicts prostate cancer treatment decision-making difficulty and satisfaction.

Authors:  Heather Orom; Louis A Penner; Brady T West; Tracy M Downs; Walter Rayford; Willie Underwood
Journal:  Psychooncology       Date:  2009-03       Impact factor: 3.894

8.  Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer.

Authors:  M L G Janssen-Heijnen; S Smulders; V E P P Lemmens; F W J M Smeenk; H J A A van Geffen; J W W Coebergh
Journal:  Thorax       Date:  2004-07       Impact factor: 9.139

9.  Low-dose rate brachytherapy of the prostate in elderly patients.

Authors:  C Chiumento; A Fiorentino; R Caivano; S Clemente; V Fusco
Journal:  Radiol Med       Date:  2012-09-17       Impact factor: 3.469

Review 10.  Optimal management of recurrent prostate cancer in older patients.

Authors:  Elizabeth R Kessler; Thomas W Flaig
Journal:  Drugs Aging       Date:  2012-11       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.